On the morning of October 8, Ruibo Biotech announced on the Hong Kong Stock Exchange that it has submitted a phase I clinical trial application for the company's siRNA product RBD3133 injection targeting INHBE in the European Union for treatment of overweight and obesity. RBD3133 injection is designed to selectively silence INHBE. Human genetics studies have shown that individuals with natural INHBE functional loss variants have healthier fat distribution, improved metabolic characteristics, and lower estimated risk of coronary heart disease and type 2 diabetes. These findings support INHBE as a promising therapeutic target for the treatment of obesity and related metabolic diseases.
Zhitongcaijing · 1d ago
Share
Listen to the news
On the morning of October 8, Ruibo Biotech announced on the Hong Kong Stock Exchange that it has submitted a phase I clinical trial application for the company's siRNA product RBD3133 injection targeting INHBE in the European Union for treatment of overweight and obesity. RBD3133 injection is designed to selectively silence INHBE. Human genetics studies have shown that individuals with natural INHBE functional loss variants have healthier fat distribution, improved metabolic characteristics, and lower estimated risk of coronary heart disease and type 2 diabetes. These findings support INHBE as a promising therapeutic target for the treatment of obesity and related metabolic diseases.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending